Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study.

[1]  B. Coventry,et al.  Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  James X. Sun,et al.  Long–Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis , 2019, Annals of Surgical Oncology.

[3]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[4]  R. Emerson,et al.  Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade , 2018, Cancer Immunology Research.

[5]  M. Phelps,et al.  Associations of High‐Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial , 2017, Clinical pharmacology and therapeutics.

[6]  B. Coventry,et al.  Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study , 2017, Annals of Surgical Oncology.

[7]  A. Testori,et al.  Diagnosis and treatment of in-transit melanoma metastases. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[8]  David T. W. Jones,et al.  Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma , 2016, Oncotarget.

[9]  P. Kam,et al.  Isolated limb infusion with melphalan and actinomycin D for melanoma: A systematic review , 2014, Journal of surgical oncology.

[10]  P. Kam,et al.  Isolated limb infusion: Technical aspects , 2014, Journal of surgical oncology.

[11]  M. Dewhirst,et al.  A multi‐institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan‐based isolated limb infusion , 2012, Cancer.

[12]  S. Mocellin,et al.  Systemic treatments for metastatic cutaneous melanoma. , 2014, The Cochrane database of systematic reviews.

[13]  P. Kam,et al.  Isolated limb perfusion and isolated limb infusion for malignant lesions of the extremities. , 2011, Current problems in surgery.

[14]  P. Kam,et al.  Does Increased Experience with Isolated Limb Infusion for Advanced Limb Melanoma Influence Outcome? A Comparison of Two Treatment Periods at a Single Institution , 2011, Annals of Surgical Oncology.

[15]  Merrick I Ross,et al.  Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Lane,et al.  Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy , 2009, Cell cycle.

[18]  M. Ross,et al.  Predictive Factors of Regional Toxicity and Serum Creatine Phosphokinase Levels After Isolated Limb Infusion for Melanoma: A Multi-Institutional Analysis , 2009, Annals of Surgical Oncology.

[19]  M. Ross,et al.  A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. , 2009, Journal of the American College of Surgeons.

[20]  P. Kam,et al.  Factors Predictive of Acute Regional Toxicity After Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma Patients , 2009, Annals of Surgical Oncology.

[21]  C. Augustine,et al.  Optimizing Melphalan Pharmacokinetics in Regional Melanoma Therapy: Does Correcting for Ideal Body Weight Alter Regional Response or Toxicity? , 2009, Annals of Surgical Oncology.

[22]  B. Vrouenraets,et al.  Isolated limb perfusion for melanoma. , 2008, Surgical oncology clinics of North America.

[23]  R. Petersen,et al.  Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion , 2008, Annals of Surgical Oncology.

[24]  A. Hill,et al.  Isolated limb infusion for melanoma. , 2007, The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland.

[25]  H. Friedman,et al.  Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. , 2003, American journal of surgery.

[26]  J. Thompson,et al.  Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy , 2001, Melanoma research.

[27]  D. Freedman,et al.  Body fat distribution and male/female differences in lipids and lipoproteins. , 1990, Circulation.

[28]  E. V. van Slooten,et al.  Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.

[29]  C. Verhoef,et al.  Perfusion and infusion for melanoma in-transit metastases in the era of effective systemic therapy. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[30]  D. Tyler,et al.  Burden of Disease Predicts Response to Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma , 2014, Annals of Surgical Oncology.

[31]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[32]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .